Fractyl Health (NASDAQ:GUTS) Given New $10.00 Price Target at Morgan Stanley

Fractyl Health (NASDAQ:GUTS) had its price target trimmed by Morgan Stanley from $18.00 to $10.00 in a research note issued to investors on Monday,Benzinga reports. The firm currently has an overweight rating on the stock.

Fractyl Health Price Performance

GUTS stock opened at $1.70 on Monday. The company has a debt-to-equity ratio of 0.60, a quick ratio of 5.57 and a current ratio of 5.58. The business has a 50-day simple moving average of $2.06 and a two-hundred day simple moving average of $2.51. The company has a market capitalization of $81.77 million and a P/E ratio of -0.14. Fractyl Health has a 52-week low of $1.68 and a 52-week high of $13.99.

Fractyl Health (NASDAQ:GUTS) last announced its earnings results on Tuesday, November 12th. The company reported ($0.48) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.50) by $0.02. The company had revenue of $0.01 million for the quarter. Research analysts expect that Fractyl Health will post -1.66 EPS for the current fiscal year.

Insider Activity

In related news, CEO Harith Rajagopalan sold 96,517 shares of the stock in a transaction that occurred on Monday, November 11th. The stock was sold at an average price of $2.47, for a total transaction of $238,396.99. Following the completion of the sale, the chief executive officer now directly owns 491,329 shares of the company’s stock, valued at approximately $1,213,582.63. This trade represents a 16.42 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, insider Jay David Caplan sold 64,197 shares of the business’s stock in a transaction on Monday, November 11th. The stock was sold at an average price of $2.47, for a total value of $158,566.59. Following the completion of the transaction, the insider now directly owns 153,544 shares in the company, valued at approximately $379,253.68. This represents a 29.48 % decrease in their position. The disclosure for this sale can be found here. Insiders sold a total of 274,032 shares of company stock worth $602,979 over the last quarter.

Hedge Funds Weigh In On Fractyl Health

Several institutional investors have recently added to or reduced their stakes in GUTS. Massachusetts Financial Services Co. MA boosted its stake in Fractyl Health by 4.9% in the third quarter. Massachusetts Financial Services Co. MA now owns 1,045,672 shares of the company’s stock valued at $2,646,000 after acquiring an additional 49,289 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Fractyl Health by 166.5% in the 3rd quarter. Geode Capital Management LLC now owns 501,476 shares of the company’s stock worth $1,269,000 after purchasing an additional 313,335 shares during the period. State Street Corp lifted its stake in Fractyl Health by 129.4% in the third quarter. State Street Corp now owns 113,415 shares of the company’s stock valued at $287,000 after purchasing an additional 63,968 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in Fractyl Health by 56.9% during the third quarter. Charles Schwab Investment Management Inc. now owns 80,664 shares of the company’s stock valued at $204,000 after purchasing an additional 29,262 shares during the period. Finally, Barclays PLC increased its position in Fractyl Health by 1,754.7% in the third quarter. Barclays PLC now owns 47,796 shares of the company’s stock worth $121,000 after buying an additional 45,219 shares during the last quarter.

About Fractyl Health

Fractyl Health, Inc, a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. The company develops Revita DMR System (Revita), an outpatient procedural therapy designed to durably modify duodenal dysfunction, a pathologic consequence of a high fat and high sugar diet, which can initiate T2D and obesity in humans.